Aldinger Jeffrey P, Dobyns Taylor, Lam Kent, Han Joseph K
Eastern Virginia Medical School, Norfolk, United States.
Expert Opin Biol Ther. 2021 Sep;21(9):1143-1149. doi: 10.1080/14712598.2021.1962282. Epub 2021 Aug 12.
Chronic rhinosinusitis with nasal polyposis (CRSwNP) poses a significant healthcare challenge, with diminished quality of life for patients and high costs and resource utilization for disease management. The understanding of CRSwNP pathophysiology has progressed with identification of various inflammatory biomarkers and subsequent development of monoclonal antibodies that target the underlying mechanisms of inflammation. Omalizumab is a biologic agent for CRSwNP treatment that targets immunoglobulin (Ig)-E. The US FDA has approved the use of omalizumab as an add-on biologic therapy for nasal polyposis in December 2020. Two Phase III clinical trials, POLYP 1 and POLYP 2, have shown that omalizumab improves both subjective patient-reported outcomes and objective physician-evaluated metrics for CRSwNP. Ongoing studies are still exploring the efficacy, safety, and cost-effectiveness of biologics for CRSwNP. Biologics will continue develop as a viable management option for CRSwNP. Omalizumab is regarded as a promising addition to current treatment strategies for refractory disease.
伴有鼻息肉的慢性鼻-鼻窦炎（CRSwNP）对医疗保健构成了重大挑战，它会降低患者的生活质量，并且疾病管理成本高昂、资源消耗巨大。随着各种炎症生物标志物的发现以及随后针对炎症潜在机制的单克隆抗体的开发，人们对CRSwNP病理生理学的认识有了进展。奥马珠单抗是一种用于治疗CRSwNP的生物制剂，其作用靶点是免疫球蛋白（Ig）-E。美国食品药品监督管理局（US FDA）于2020年12月批准将奥马珠单抗作为鼻息肉的附加生物疗法使用。两项III期临床试验POLYP 1和POLYP 2表明，奥马珠单抗可改善CRSwNP患者报告的主观结局以及医生评估的客观指标。正在进行的研究仍在探索生物制剂治疗CRSwNP的疗效、安全性和成本效益。生物制剂将继续作为CRSwNP的一种可行管理选择而不断发展。奥马珠单抗被认为是难治性疾病当前治疗策略中一个有前景的补充。
